AstraZeneca stock trades at EUR 142.88 with 362,423 shares versus 3,369,364 average

Published on 10/09/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock costs EUR 142.88 on October 9, 2026 versus EUR 141.60. Volume is 362,423 shares versus a 3,369,364 average.

Key points in brief

AstraZeneca stock was trading at EUR 142.88 at Lang & Schwarz on October 9, 2026 at 4:02 p.m. CEST, down 0.90 percent versus EUR 141.60.
The quote's bid was EUR 142.75 and ask EUR 143.00, while reported volume was 362,423 shares against a 3,369,364 average.
AstraZeneca's market capitalization was USD 247.6 billion and its P/E ratio was 23.93 as of October 9, 2026.
Jefferies maintained a Buy rating and a GBp 17,500 target on October 7, 2026.
Third-quarter 2026 results are scheduled for October 30, 2026.

Pop-Art-Comicbild eines Wissenschaftlers mit Spritze und Impfstofffläschchen — AstraZeneca plc (ISIN GB0009895292) prägt mit Impfstoffen und Medikamenten die globale Gesundheitsversorgung und Onkologie-Behandlung, Illustration mit AI erstellt.

At 4:02 p.m. CEST, AstraZeneca (ISIN GB0009895292) was trading at EUR 142.88 at Lang & Schwarz on October 9, 2026, down 0.90 percent versus the EUR 141.60 prior close. The price remained an intraday indication for investors in Germany, with the bid at EUR 142.75 and the ask at EUR 143.00.

Trading activity stays below average

Volume stood at 362,423 shares on October 9, 2026, compared with an average volume of 3,369,364 shares. The gap between current activity and the average makes the day's price move a relatively small signal on its own.

Stock remains near its yearly low

On the Nasdaq, AstraZeneca was last quoted at USD 159.67 at 10:05 a.m. EDT on October 9, 2026. The same quote context placed the 52-week range at USD 153.41 to USD 212.71, while the Lang & Schwarz price remained a separate euro quotation.

AstraZeneca's Nasdaq-listed price was down 10.60 percent year to date as of October 2, 2026. The stock's 52-week range and year-to-date performance show a wider performance gap than the 0.90 percent daily decline in the German trading perspective.

Valuation and analyst target

AstraZeneca's market capitalization was USD 247.6 billion on October 9, 2026, and its price-to-earnings ratio was 23.93. These figures describe the Nasdaq-listed security in US dollars and are not combined with the euro quotation.

According to Yahoo Finance on October 7, 2026, Jefferies maintained a Buy rating and a GBp 17,500 price target. The broker expected third-quarter revenue to be 1.00 percent above Visible Alpha consensus and core earnings before interest and tax to be 3.00 percent above expectations.

Comparison with peers

AstraZeneca: minus 0.90 percent, P/E 23.93, market capitalization USD 247.6 billion

GSK (NYSE, USD): plus 0.19 percent, P/E 14.82, market capitalization USD 93.4 billion

Novartis (NYSE, USD): plus 0.21 percent, P/E 21.92, market capitalization USD 272.6 billion

Results date is October 30

According to The Wall Street Journal, AstraZeneca's next reporting date is October 30, 2026, for third-quarter results. That scheduled date provides the next fixed calendar marker for the stock after the October 9 trading session.

EUR 142.88 at Lang and Schwarz

AstraZeneca was trading at EUR 142.88 at Lang & Schwarz on October 9, 2026 at 4:02 p.m. CEST, down 0.90 percent versus the prior close of EUR 141.60. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.